ライフサイエンスコーパス: subconjunctival

1 Eyes with previous failed GDD underwent subconjunctival 0.3 cc (0.4 mg/ml) mitomycin C, tenonect

2 Subconjunctival 5-fluorouracil injections were given pos

3 Subconjunctival 5-FU injection was performed postoperati

4 ng/ml) injection when compared to posterior subconjunctival (76+/-6 ng/ml) and intravitreal (108+/-3

5 Subconjunctival administration in rat eyes was by inject

6 ocular drug levels for at least 7 days after subconjunctival administration in rats, and prevented co

7 Subconjunctival administration of liposome-encapsulated

8 Subconjunctival administration of neutralizing Ab to IL-

9 Subconjunctival administration of neutralizing antibody

10 Furthermore, subconjunctival administration of optimal range dosages

11 The positive results with subconjunctival administration of P-IQACRG suggest that

12 Subconjunctival administration of rhuPEDF or 34-mer at 0

13 Subconjunctival administration of TPT in FS to one eye a

14 A single subconjunctival administration of VP hybridized within P

15 trast, providing additional Slit2 protein by subconjunctival administration resulted in significantly

16 After subconjunctival administration, both budesonide-PLA nano

17 on choroidal neovascularization (CNV) after subconjunctival administration.

18 ion was performed, with recipients receiving subconjunctival alpha-MSH or sham injections twice weekl

19 A combination of subconjunctival and i.p. administration of IL-1beta poly

20 Administration of flagellin via the subconjunctival and intraperitoneal routes 24 h prior to

21 and 2-fold (p = 0.03) higher than posterior subconjunctival and intravitreal injections, respectivel

22 d at 10 and 27.5 minutes, respectively, with subconjunctival and intravitreal injections.

23 ed-dropless postoperative protocol involving subconjunctival and posterior sub-Tenon's injections onl

24 eviews currently used techniques of topical, subconjunctival and regional block anesthesia used in op

25 Our results indicated that subconjunctival and subcutaneous injection of HC-HA/PTX3

26 Subconjunctival and submandibular lymph node macrophages

27 s, ab interno trabeculotomy with Trabectome, subconjunctival and supraciliary drainage devices, and e

28 Anterior subconjunctival and topical ketorolac were compared to c

29 The successful use of subconjunctival anesthesia demonstrates a new alternativ

30 a to a combination of topical anesthesia and subconjunctival anesthesia for phacoemulsification.

31 The subconjunctival anesthesia with local anesthetics is con

32 tic with cotton swab compression, 27% used a subconjunctival anesthetic, and 31% used an anesthetic g

33 uenced by the use of intracameral (0.898) or subconjunctival antibiotics (0.331), whereas the use of

34 newer antibiotics and the appropriateness of subconjunctival antibiotics are reviewed.

35 ative antibiotics, intracameral antibiotics, subconjunctival antibiotics, systemic antibiotics, and p

36 r more effective than traditional topical or subconjunctival approaches.

37 hesia with 0.5% tetracaine hydrochloride and subconjunctival balanced salt solution injection (Contro

38 Patients were randomized to receive subconjunctival bevacizumab (2.5 mg/0.1 ml) or placebo a

39 To describe the use of subconjunctival bevacizumab (SCB) injection in the combi

40 Eighteen eyes underwent trabeculectomy with subconjunctival bevacizumab injection (2.5 mg/0.1 mL), a

41 Subconjunctival bevacizumab may offer an adjunctive meas

42 Both topical and subconjunctival bevacizumab treatment reduced neovascula

43 Only subconjunctival bevacizumab treatment resulted in signif

44 Adjunctive subconjunctival bevacizumab with trabeculectomy is effec

45 Interestingly, mouse neonates given a subconjunctival BMP4 injection displayed a phenotype res

46 irus-40 T-antigen-positive mice received six subconjunctival CA-4P injections at doses of 0.5, 1.0, 1

47 platin (18.7 mg/kg of body weight), a single subconjunctival carboplatin injection (5.0 mg/400 microL

48 To evaluate the safety of different doses of subconjunctival cetuximab in rabbits.

49 tcome (log rank test, P < 0.001) and reduced subconjunctival collagen deposition (P < 0.01) compared

50 local anti-inflammatory therapy (topical or subconjunctival corticosteroids), and 2 patients receive

51 irmed excellent efficacy and tolerability to subconjunctival corticosteroids.

52 rom each group received either of 2 doses of subconjunctival CsA (group A, low-dose CsA; group B, hig

53 High-dose subconjunctival CsA implants do not significantly affect

54 y, either during a cycle of carboplatin (six subconjunctival deliveries) or after the completed cycle

55 Subconjunctival delivery of CA-4P is associated with ext

56 Subconjunctival delivery of neutralizing antibody agains

57 Subconjunctival delivery of paclitaxel effectively inhib

58 onjunctiva, cornea, retina, and sclera after subconjunctival delivery.

59 y invasive glaucoma surgery which provides a subconjunctival drainage pathway and decreases intraocul

60 Bleb characteristics, the presence of subconjunctival drainage, and local reaction to treatmen

61 nd efficient method to restore aqueous humor subconjunctival drainage.

62 (P = .02), filamentary keratitis (P = .02), subconjunctival fibrosis (P = .02), and a higher Nationa

63 with diabetes, LSCD, filamentary keratitis, subconjunctival fibrosis, and a high NIH score were at h

64 nt pterygium excision followed by removal of subconjunctival fibrovascular tissue and application of

65 (72.7%) but was a temporizing measure before subconjunctival filtering surgery.

66 Subconjunctival Fl-PEDF or Fl-ovalbumin administration i

67 redness, trauma without eye involvement, and subconjunctival haemorrhage.

68 Intraoperative complications were subconjunctival hemorrhage (290, 26.2%), anterior capsul

69 intervention, were irritation (n = 312) and subconjunctival hemorrhage (n = 284).

70 ned bruises (positive LR range, 2.0-66), and subconjunctival hemorrhage (positive LR range, 5.4-130)

71 ts were recorded, with the exception of mild subconjunctival hemorrhage at the injection site.

72 Among structural manifestations, subconjunctival hemorrhage had a prevalence of 0.18 (95%

73 ted with the surgical procedure and included subconjunctival hemorrhage in 8 patients and ocular hype

74 the buttocks or neck, patterned bruises, and subconjunctival hemorrhage in young children should aler

75 During acute phase, subconjunctival hemorrhage is a relatively common findin

76 on (p = 0.001) and a significant increase in subconjunctival hemorrhage related to the injection (p <

77 raocular pressure (IOP), exposure keratitis, subconjunctival hemorrhage, a sore throat, and a transie

78 is, together with conjunctival membranes and subconjunctival hemorrhage, were the earliest signs, pre

79 carried a higher risk of spontaneous-relief subconjunctival hemorrhage.

80 chalazions (3.71%), corneal ulcers (3.01%), subconjunctival hemorrhages (2.96%), corneal foreign bod

81 lion visits were for conjunctivitis (28.0%), subconjunctival hemorrhages (3.0%), and styes (3.8%).

82 e inconsistent between the two groups, while subconjunctival hemorrhages were more common in the sutu

83 This effect was blocked by subconjunctival hexamethonium.

84 MMC-treated tissue demonstrated subconjunctival hypocellularity associated with peripher

85 6 mice after DS, and this was exacerbated by subconjunctival IFN-gamma injection.

86 on, failure of Mucin 5ac (Muc5ac) synthesis, subconjunctival inflammation and epidermal metaplasia in

87 Subconjunctival infusions failed to produce detectable l

88 As an alternative, subconjunctival infusions of drug to the episclera of th

89 The effects of subconjunctival-injected parstatin on corneal neovascula

90 caine group experienced more pain during the subconjunctival injection (p = 0.001) and a significant

91 Both techniques of MMC delivery (subconjunctival injection and direct scleral application

92 of six New Zealand white rabbits was given a subconjunctival injection at the 12-o'clock position wit

93 ocular antibiotic accumulation with a single subconjunctival injection compared to 3x daily eye drops

94 Subconjunctival injection for each group (XG-102 90 mug,

95 e VEGFR1_MO, STD MO and PBS groups following subconjunctival injection in mice that underwent normal

96 cinolone acetonide, and PBS groups following subconjunctival injection in mice that underwent penetra

97 40 mug) was administered every 3 months as a subconjunctival injection in only one randomly assigned

98 rance of the nanoparticles in the eyes after subconjunctival injection in vivo.

99 Anterior subconjunctival injection led to high, though short-live

100 Subconjunctival injection may be a useful approach for d

101 -inflammatory drug (NSAID) or intraoperative subconjunctival injection of 2 mg triamcinolone acetonid

102 The time course and extent of mydriasis from subconjunctival injection of 2% pirenzepine were determi

103 After general anesthesia rabbits received a subconjunctival injection of 2.5 mg in 0.5 ml, 5 mg in 1

104 Patients were administered a single subconjunctival injection of 250 muL XG-102 90 mug (n =

105 The study drug was administered as a single subconjunctival injection of 30 muL (1320 mug) sirolimus

106 eedling with HA-5FU mixture or needling with subconjunctival injection of 5FU solution alone.

107 The right eye of 15 mice received a single subconjunctival injection of a 1.5-microL solution of 0.

108 ch case, patients were administered a 0.5 cc subconjunctival injection of a 1:1 Cefazolin (50 mg/cc):

109 Finally, we demonstrate that a subconjunctival injection of a Gal-8 inhibitor markedly

110 ed keratitis was significantly reduced after subconjunctival injection of a monoclonal antibody (mAb)

111 Intra-Tenon or subconjunctival injection of a solution of mitomycin C (

112 nase modulation after AA treatment, a single subconjunctival injection of AA (300 microg) was deliver

113 Conversely, subconjunctival injection of Ab to ICAM-1 did not impair

114 Subconjunctival injection of Ab to PECAM-1 significantly

115 ek-old, LH(BETA)T(AG) mice received a single subconjunctival injection of anecortave acetate (1200, 6

116 ek-old, LH(BETA)T(AG) mice received a single subconjunctival injection of anecortave acetate (600, 30

117 The fellow eye was given a subconjunctival injection of balanced salt solution.

118 ning suturing after receiving a preoperative subconjunctival injection of bevacizumab in his right ey

119 Postoperative subconjunctival injection of bevacizumab is associated w

120 Subconjunctival injection of cetuximab with the administ

121 Depletion of local macrophages, through subconjunctival injection of clodronate liposome, attenu

122 We induced mast cell degranulation by local subconjunctival injection of compound 48/80.

123 Subconjunctival injection of disodium cromoglycate signi

124 Subconjunctival injection of DSP-NP is a promising appro

125 16-week-old mice were treated with a single subconjunctival injection of either anecortave acetate (

126 Subconjunctival injection of HA-5FU to revive bleb funct

127 help prove the concept that subcutaneous and subconjunctival injection of HC-HA/PTX3 is a novel appro

128 Anterior subconjunctival injection of ketorolac produced high int

129 s showed that different suturing techniques, subconjunctival injection of long-acting steroid, and ta

130 these adverse effects just few minutes after subconjunctival injection of mepivacaine 2% solution (Sc

131 CpG DNA, which binds TLR9, was tested after subconjunctival injection of mice with control or CpG DN

132 After subconjunctival injection of mitomycin C (MMC), a novel

133 Subconjunctival injection of mitomycin C in the rabbit p

134 Subconjunctival injection of MMP13i prior to P. aerugino

135 Strikingly, subconjunctival injection of P-IQACRG was very effective

136 ncluded topical PA with or without NSAID and subconjunctival injection of TA (Kenalog; Bristol-Myers-

137 In the mouse cornea, subconjunctival injection of the morpholino-inhibited co

138 Dutch-belted rabbits received a subconjunctival injection of triamcinolone acetonide to

139 A single subconjunctival injection of XG-102 at the end of ocular

140 randomized to MMC delivered by preoperative subconjunctival injection or by intraoperative direct sc

141 venous delivery than after focal delivery by subconjunctival injection or CCI.

142 oroid, vitreous humor, and optic nerve after subconjunctival injection or iontophoretic carboplatin d

143 ix cycles of 5.0 mg carboplatin delivered by subconjunctival injection or six transscleral carboplati

144 to prevent corneal graft rejection following subconjunctival injection provided initially during tran

145 red to the mouse retina and uveal tissues by subconjunctival injection through transscleral diffusion

146 either mBD1 or mBD2 small interfering RNA by subconjunctival injection together with topical applicat

147 ic preoperative antibiotics or postoperative subconjunctival injection was associated with a 40% to 5

148 lated-P-IQACRG delivered via intravitreal or subconjunctival injection was demonstrated by avidin-bio

149 on (Control group) or topical anesthesia and subconjunctival injection with 2% lidocaine (Lidocaine g

150 on of neutrophil recruitment was achieved by subconjunctival injection with an antibody against macro

151 Infected BALB/c mice also were tested after subconjunctival injection with recombinant murine (rm)ST

152 with HSV-1 were vaccinated periocularly (by subconjunctival injection) with gD1 and adjuvant, gD2 an

153 Ketorolac was administered by anterior subconjunctival injection, posterior periocular injectio

154 It was reported that, after subconjunctival injection, RNA nanoparticles with tri-wa

155 to achieve high intraocular penetration with subconjunctival injection.

156 er: suprachoroidal > intravitreal >posterior subconjunctival injection.

157 Cs were selectively depleted by timed local (subconjunctival) injection of diphtheria toxin (DT) into

158 Daily subconjunctival injections (0.01-10 pmol/d protein) were

159 = 5) 10 weeks of age received two 20-microL subconjunctival injections delivered with a 72-hour inte

160 Subconjunctival injections of 0.0002% to 0.2% pirenzepin

161 Subconjunctival injections of 0.002% or less pirenzepine

162 Subconjunctival injections of 0.02% or greater pirenzepi

163 or patients allergic to penicillin, separate subconjunctival injections of 0.25 cc each of Vancomycin

164 d to receive a postoperative course of seven subconjunctival injections of bevacizumab (1.25 mg, 25 m

165 d to receive a postoperative course of seven subconjunctival injections of CAT-152 (1 mg/mL), 5-FU (5

166 ce was tested by depleting macrophages using subconjunctival injections of clodronate-containing lipo

167 Control mice received two subconjunctival injections of DMSO or of saline solution

168 concentration of 0.2 mg/mL or postoperative subconjunctival injections of either ilomastat or phosph

169 randomly allocated to receive postoperative subconjunctival injections of either phosphate-buffered

170 group of mice of both strains also received subconjunctival injections of exogenous IFN-gamma or veh

171 BETA)T(AG) mice were treated with six serial subconjunctival injections of focally delivered carbopla

172 g, 16-week-old mice were treated with single subconjunctival injections of the selective vascular-tar

173 ocal recombinant Gal-1 (rGal-1) treatment by subconjunctival injections significantly diminishes P. a

174 arboplatin was administered through biweekly subconjunctival injections to right eyes only for 3 week

175 when compared to intravitreal and posterior subconjunctival injections.

176 Subconjunctival inoculation of spantide I during the cli

177 Subconjunctival inoculation of spantide I, SP receptor a

178 n of endogenous MIP-2 and KC was achieved by subconjunctival inoculation of the appropriate antibody.

179 The addition of subconjunctival lidocaine injection to topical anesthesi

180 s, use of a strict no-talking policy, use of subconjunctival lidocaine, and topical antibiotic use we

181 informed about such rare complications after subconjunctival local anesthetics administration.

182 conjunctiva, epidermis, hair follicles, and subconjunctival lymphoid follicles.

183 ft eye with a slight elevation, suggesting a subconjunctival mass.

184 es are required for the MicroShunt and other subconjunctival microstent devices to evaluate their use

185 failure may help guide patient selection for subconjunctival minimally invasive glaucoma surgery in p

186 Subconjunctival mitomycin C injection may cause limbal s

187 Following subconjunctival Mitomycin C, an ab-interno MIMS procedur

188 protocol of intraoperative and postoperative subconjunctival MMC injections.

189 018 to 2019 under a standardized protocol of subconjunctival MMC injections.

190 country, the American patients have not had subconjunctival nodules but have manifested more invasiv

191 its, catheters were placed anteriorly in the subconjunctival or intrascleral space and infused with G

192 o-penta-acetic acid (Gd-DTPA) infused in the subconjunctival or intrascleral space was investigated b

193 Focal administration of carboplatin using subconjunctival or noninvasive CCI safely and effectivel

194 ere noted; procedure-related adverse events (subconjunctival or subretinal haemorrhage and mild cell

195 Dawley rats after suprachoroidal, posterior subconjunctival, or intravitreal injections.

196 Subconjunctival parstatin inhibited corneal neovasculari

197 S in one eye was injected into the posterior subconjunctival (periocular) space in rats under anesthe

198 ddition, these data prompt the proposal that subconjunctival protein delivery may represent a feasibl

199 art review of 4 patients diagnosed with late subconjunctival relapse of previously resected iris mela

200 dian of 2.5 years (mean: 7.7 years) from the subconjunctival relapse, no further episodes of intraocu

201 ls were treated with intravenous (IV) and/or subconjunctival (SC) Cl(2)MDP-LIP or PBS-LIP at the foll

202 Macrophage depletion was performed by subconjunctival (SC) delivery of liposomal clodronate.

203 terior subtenon (PST), retrobulbar (RB), and subconjunctival (SC) injection.

204 benefit as a postoperative agent to prevent subconjunctival scarring after glaucoma filtration surge

205 ificantly improved surgical outcome, reduced subconjunctival scarring, and minimized the risk of corn

206 ter virus infection was achieved by repeated subconjunctival (SCJ) and/or intravenous (IV) injection

207 ion through transscleral diffusion following subconjunctival (SCT) injection in comparison to its sun

208 Subconjunctival (SCT) injection is a less invasive optio

209 Subconjunctival (SCT) injection of Sunb-malate MS provid

210 Subconjunctival sirolimus appears to be well tolerated i

211 Subconjunctival sirolimus leads to a short-term reductio

212 Subconjunctival sirolimus may not be beneficial in the p

213 Repeated subconjunctival sirolimus was well-tolerated in patients

214 vice providing an ab-interno approach to the subconjunctival space for aqueous drainage and reduction

215 limination rate constant of Gd-DTPA from the subconjunctival space into the episcleral veins and conj

216 Cultured RPE cells implanted in the subconjunctival space of syngeneic mice elicited an inte

217 Gd-DTPA were manufactured and placed in the subconjunctival space on the episclera or in the vitreou

218 n, continuous release of cyclosporine in the subconjunctival space with the episcleral implant was an

219 ass through the trabeculectomy site into the subconjunctival space, and an extra amount was injected

220 These procedures drain aqueous into the subconjunctival space, and they are highly effective at

221 anterior chamber, the subretinal space, the subconjunctival space, and underneath the kidney capsule

222 r surface, corneal stroma, anterior chamber, subconjunctival space, suprachoroidal space, vitreous bo

223 f newborn C57BL/6 mice were implanted in the subconjunctival space, the anterior chamber, or the subr

224 lear cornea incision and was confined to the subconjunctival space.

225 (also known as InnFocus(R) MicroShunt) is a subconjunctival stent implanted ab externo via a minimal

226 d to control as well as topical and anterior subconjunctival steroid treatments in uveitis induced by

227 let cell expansion that invaginates into the subconjunctival stroma in the mouse eye.

228 nd promoted the formation of a nearly normal subconjunctival stroma.

229 ells than normal specimens were noted in CCh subconjunctival tissue and Tenon's capsule.

230 Depletion of macrophages in the subconjunctival tissue before corneal infection was not

231 arying levels of TGF-beta in the aqueous and subconjunctival tissues may thus significantly modify th

232 terally with a single 30-microL injection of subconjunctival TPT in FS (0.025, 0.05, 0.1, 0.2, 0.4, 0

233 lar area was 55% (P < 0.05) by week 8 in the subconjunctival treatment group and 33% (P = 0.15) in th

234 However, in the subconjunctival treatment group, 33% of corneal grafts s

235 models were used to evaluate the effects of subconjunctival Treg injections in vivo.

236 In vivo, subconjunctival Treg injections significantly reduced co

237 with systemic dexamethasone or intravitreal/subconjunctival triamcinolone.

238 Overall, patient was medically treated subconjunctival vancomycin, gentamicin and moxifloxacin

239 isk host beds, and graft recipients received subconjunctival vascular endothelial growth factor (VEGF

240 Postoperative subconjunctival wound healing remains the commonest caus